Development of Selective FXIa Inhibitors Based on Cyclic Peptides and Their Application for Safe Anticoagulation

Area of Science:

• Biochemistry
• Pharmacology
• Thrombosis research

Background:

• Coagulation factor XI (FXI) is a potential target for safer anticoagulants.
• Current anticoagulants carry risks of severe bleeding.
• Developing FXI inhibitors can mitigate these risks.

Purpose of the Study:

• To develop and characterize a novel cyclic peptide inhibitor of FXI.
• To evaluate its efficacy and safety profile compared to existing anticoagulants.
• To assess its potential for clinical application in anticoagulation therapy.

Main Methods:

• Design and synthesis of a cyclic peptide inhibitor targeting FXI.
• In vitro inhibition assays to determine binding affinity (Ki) and potency against activated FXI (FXIa).
• In vivo studies involving PEGylation to extend half-life and ex vivo hemodialysis models to validate anticoagulant effects.

Main Results:

• The cyclic peptide inhibitor potently and selectively inhibited FXIa (Ki = 2.8 ± 0.5 nM).
• Achieved anticoagulation comparable to heparin but with a broader therapeutic range.
• PEGylation extended the peptide's plasma half-life, enabling sustained FXIa inhibition in vivo.
• Validated anticoagulant effects in an ex vivo human hemodialysis model.

Conclusions:

• Peptide-based inhibitors can effectively and selectively target FXI.
• This cyclic peptide inhibitor represents a promising candidate for developing safer anticoagulation therapies.
• Further development could lead to improved treatments with reduced bleeding complications.